Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).

Authors

John M. Varlotto

Edwards Comprehensive Cancer Center, Huntington, WV

John M. Varlotto , Zhuoxin Sun , Suresh S. Ramalingam , Heather A. Wakelee , Christine M. Lovly , Kurt R. Oettel , Gregory A. Masters , Nate Pennell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).

First Author: Matt D. Galsky

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE.

First Author: Thomas Powles

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.

First Author: Jarushka Naidoo

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Treatment interruptions and discontinuations among patients with stage III unresectable non–small cell lung cancer treated with durvalumab at the Veterans Health Administration.

First Author: Munaf Alkadimi